On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.

Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for subcutaneous (SC) administration via a wearable, single-use, pre-programmed on-body infusor for outpatient ...

Some health conditions may increase your risk of other serious complications. According to an expert, high blood pressure may ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Magnesium citrate: A highly absorbable form of magnesium, this is usually used to treat occasional constipation. This can be ...

Damage or injury to nerves causes a painful condition called neuropathy. This article reviews the safety and evidence behind ...

The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into ...

A study investigated patients with chronic kidney disease (CKD) and their risk for bone fractures with clinical implications.

Coach Justin Mihaly shared insights on Jodi Vance’s passing, warning about diuretics and their potential risks in ...

The second mechanism is post-diuretic effect, a compensatory sodium-retention process that begins as the diuretic action wanes. [4] Technically, postdiuretic sodium retention is not diuretic ...